{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:02:47Z","timestamp":1785578567530,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Qianxinan Science and Technology Planning Project","award":["2023-3-5"],"award-info":[{"award-number":["2023-3-5"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81560269"],"award-info":[{"award-number":["81560269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Laboratory of Respiratory Diseases","award":["SKLRD-OP-202208"],"award-info":[{"award-number":["SKLRD-OP-202208"]}]},{"name":"Guizhou Provincial Science and Technology Projects","award":["GPPH-NSFC-2020-6"],"award-info":[{"award-number":["GPPH-NSFC-2020-6"]}]},{"name":"Guizhou Provincial Science and Technology Projects","award":["GPPH-NSFC-2020-7"],"award-info":[{"award-number":["GPPH-NSFC-2020-7"]}]},{"name":"Guizhou Provincial Science and Technology Projects","award":["GCC[2022]037-1"],"award-info":[{"award-number":["GCC[2022]037-1"]}]},{"name":"Guizhou Immunotherapy Research Talent Base","award":["RCJD2018-11"],"award-info":[{"award-number":["RCJD2018-11"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2019PT320003"],"award-info":[{"award-number":["2019PT320003"]}]},{"name":"Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy","award":["ZDSYS20210623091811035"],"award-info":[{"award-number":["ZDSYS20210623091811035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s11010-024-04966-6","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T14:02:23Z","timestamp":1710943343000},"page":"445-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combinational delivery of TLR4 and TLR7\/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor"],"prefix":"10.1007","volume":"480","author":[{"given":"Mengjiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglv","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"4966_CR1","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24:1994\u20132007. https:\/\/doi.org\/10.1038\/s41590-023-01659-y","journal-title":"Nat Immunol"},{"key":"4966_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.121564","volume":"324","author":"Q Wang","year":"2024","unstructured":"Wang Q, Jiang H, Zhang H et al (2024) Beta-glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models. Carbohydr Polym 324:121564. https:\/\/doi.org\/10.1016\/j.carbpol.2023.121564","journal-title":"Carbohydr Polym"},{"key":"4966_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1\u201322. https:\/\/doi.org\/10.1146\/annurev-immunol-100311-102839","journal-title":"Annu Rev Immunol"},{"key":"4966_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480\u2013489. https:\/\/doi.org\/10.1038\/nature10673","journal-title":"Nature"},{"key":"4966_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","volume":"26","author":"BM Allen","year":"2020","unstructured":"Allen BM, Hiam KJ, Burnett CE et al (2020) Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med 26:1125\u20131134. https:\/\/doi.org\/10.1038\/s41591-020-0892-6","journal-title":"Nat Med"},{"key":"4966_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, Lu S, Zhang H, Zhang L, Dai Z, Kaufman DS, Zhang J (2023) Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol 41:907\u2013922. https:\/\/doi.org\/10.1016\/j.tibtech.2023.02.003","journal-title":"Trends Biotechnol"},{"key":"4966_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B (2016) Dendritic cells and cancer immunity. Trends Immunol 37:855\u2013865. https:\/\/doi.org\/10.1016\/j.it.2016.09.006","journal-title":"Trends Immunol"},{"key":"4966_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117580","volume":"254","author":"M Sadeghzadeh","year":"2020","unstructured":"Sadeghzadeh M, Bornehdeli S, Mohahammadrezakhani H, Abolghasemi M, Poursaei E, Asadi M, Zafari V, Aghebati-Maleki L, Shanehbandi D (2020) Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci 254:117580. https:\/\/doi.org\/10.1016\/j.lfs.2020.117580","journal-title":"Life Sci"},{"key":"4966_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12026-017-8931-1","volume":"65","author":"J Constantino","year":"2017","unstructured":"Constantino J, Gomes C, Falc\u00e3o A, Neves BM, Cruz MT (2017) Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res 65:798\u2013810. https:\/\/doi.org\/10.1007\/s12026-017-8931-1","journal-title":"Immunol Res"},{"key":"4966_CR10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3389\/fimmu.2019.02393","volume":"10","author":"J Fucikova","year":"2019","unstructured":"Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R (2019) Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. Front Immunol 10:2393. https:\/\/doi.org\/10.3389\/fimmu.2019.02393","journal-title":"Front Immunol"},{"key":"4966_CR11","doi-asserted-by":"publisher","first-page":"2195019","DOI":"10.1080\/22221751.2023.2195019","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Guan F, Miller H et al (2023) The role of dendritic cells in COVID-19 infection. Emerg Microbes Infect 12:2195019. https:\/\/doi.org\/10.1080\/22221751.2023.2195019","journal-title":"Emerg Microbes Infect"},{"key":"4966_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N (2017) Dendritic cell-based immunotherapy. Cell Res 27:74\u201395. https:\/\/doi.org\/10.1038\/cr.2016.157","journal-title":"Cell Res"},{"key":"4966_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J Immunol 200:443\u2013449. https:\/\/doi.org\/10.4049\/jimmunol.1701024","journal-title":"J Immunol"},{"key":"4966_CR14","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-23-0235","volume":"29","author":"DJ Chung","year":"2023","unstructured":"Chung DJ, Shah N, Wu J et al (2023) Randomized Phase II trial of dendritic cell\/myeloma fusion vaccine with lenalidomide maintenance after upfront autologous hematopoietic cell transplantation for multiple myeloma: BMT CTN 1401. Clin Cancer Res 29:4784\u20134796. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0235","journal-title":"Clin Cancer Res"},{"key":"4966_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","volume":"11","author":"A Gardner","year":"2020","unstructured":"Gardner A, de Mingo P\u00c1, Ruffell B (2020) Dendritic cells and their role in immunotherapy. Front Immunol 11:924. https:\/\/doi.org\/10.3389\/fimmu.2020.00924","journal-title":"Front Immunol"},{"key":"4966_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nri2173","volume":"7","author":"PJ Tacken","year":"2007","unstructured":"Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790\u2013802. https:\/\/doi.org\/10.1038\/nri2173","journal-title":"Nat Rev Immunol"},{"key":"4966_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","volume":"34","author":"B Besse","year":"2023","unstructured":"Besse B, Felip E, Garcia Campelo R et al (2023) Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol 34:920\u2013933. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.006","journal-title":"Ann Oncol"},{"key":"4966_CR18","doi-asserted-by":"publisher","first-page":"14186","DOI":"10.1038\/s41598-017-14655-8","volume":"7","author":"Y Nie","year":"2017","unstructured":"Nie Y, Yang TA, Han Z, Xin H, Chen X, Oppenheim JJ (2017) Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors. Sci Rep 7:14186. https:\/\/doi.org\/10.1038\/s41598-017-14655-8","journal-title":"Sci Rep"},{"key":"4966_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108345","volume":"101","author":"M Jiang","year":"2021","unstructured":"Jiang M, Liu J, Yang D et al (2021) A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer. Int Immunopharmacol 101:108345. https:\/\/doi.org\/10.1016\/j.intimp.2021.108345","journal-title":"Int Immunopharmacol"},{"key":"4966_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.4049\/jimmunol.2200371","volume":"210","author":"MM Alam","year":"2023","unstructured":"Alam MM, Gower T, Jiang M, Oppenheim JJ, Yang D (2023) A therapeutic vaccine in combination with cyclic GMP-AMP cures more differentiated melanomas in mice. J Immunol 210:1428\u20131436. https:\/\/doi.org\/10.4049\/jimmunol.2200371","journal-title":"J Immunol"},{"key":"4966_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082366","author":"S Nahar","year":"2023","unstructured":"Nahar S, Huang Y, Nagy BA, Zebala JA, Maeda DY, Rudloff U, Oppenheim JJ, Yang D (2023) Regression and eradication of triple-negative breast carcinoma in 4T1 mouse model by combination immunotherapies. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15082366","journal-title":"Cancers (Basel)"},{"key":"4966_CR22","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1021\/acsnano.3c03195","volume":"17","author":"Y Huang","year":"2023","unstructured":"Huang Y, Nahar S, Alam MM, Hu S, McVicar DW, Yang D (2023) Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring TheraVac elicit tumor-specific immunity for colon tumor treatment. ACS Nano 17:19740\u201319752. https:\/\/doi.org\/10.1021\/acsnano.3c03195","journal-title":"ACS Nano"},{"key":"4966_CR23","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/neuonc\/noad088","volume":"25","author":"KM Hotchkiss","year":"2023","unstructured":"Hotchkiss KM, Batich KA, Mohan A, Rahman R, Piantadosi S, Khasraw M (2023) Dendritic cell vaccine trials in gliomas: untangling the lines. Neurooncology 25:1752\u20131762. https:\/\/doi.org\/10.1093\/neuonc\/noad088","journal-title":"Neurooncology"},{"key":"4966_CR24","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet MJ, Di Pilato M, Garris C, Mempel TR (2023) Dendritic cells as shepherds of T cell immunity in cancer. Immunity 56:2218\u20132230. https:\/\/doi.org\/10.1016\/j.immuni.2023.08.014","journal-title":"Immunity"},{"key":"4966_CR25","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1038\/s41467-020-19833-3","volume":"11","author":"NF Kuhn","year":"2020","unstructured":"Kuhn NF, Lopez AV, Li X, Cai W, Daniyan AF, Brentjens RJ (2020) CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat Commun 11:6171. https:\/\/doi.org\/10.1038\/s41467-020-19833-3","journal-title":"Nat Commun"},{"key":"4966_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl F, Meiser P, Donakonda S et al (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56:1341\u201358.e11. https:\/\/doi.org\/10.1016\/j.immuni.2023.05.011","journal-title":"Immunity"},{"key":"4966_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044002","author":"O Habanjar","year":"2023","unstructured":"Habanjar O, Bingula R, Decombat C, Diab-Assaf M, Caldefie-Chezet F, Delort L (2023) Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24044002","journal-title":"Int J Mol Sci"},{"key":"4966_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","volume":"36","author":"I Etxeberria","year":"2019","unstructured":"Etxeberria I, Bola\u00f1os E, Quetglas JI et al (2019) Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells. Cancer Cell 36:613\u201329.e7. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.006","journal-title":"Cancer Cell"},{"key":"4966_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X (2023) Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther 8:283. https:\/\/doi.org\/10.1038\/s41392-023-01557-7","journal-title":"Signal Transduct Target Ther"},{"key":"4966_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-019-0503-6","volume":"7","author":"C-Y Chen","year":"2019","unstructured":"Chen C-Y, Ueha S, Ishiwata Y et al (2019) Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice. J Immunother Cancer 7:21. https:\/\/doi.org\/10.1186\/s40425-019-0503-6","journal-title":"J Immunother Cancer"},{"key":"4966_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002408","author":"C Anfray","year":"2021","unstructured":"Anfray C, Mainini F, Digifico E et al (2021) Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002408","journal-title":"J Immunother Cancer"},{"key":"4966_CR32","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3389\/fimmu.2018.02982","volume":"9","author":"MM Alam","year":"2018","unstructured":"Alam MM, Yang D, Trivett A, Meyer TJ, Oppenheim JJ (2018) HMGN1 and R848 synergistically activate dendritic cells using multiple signaling pathways. Front Immunol 9:2982. https:\/\/doi.org\/10.3389\/fimmu.2018.02982","journal-title":"Front Immunol"},{"key":"4966_CR33","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.18632\/aging.204941","volume":"15","author":"Z Gao","year":"2023","unstructured":"Gao Z, Zhang Q, Chen H, Chen J, Kang J, Yu H, Song Y, Zhang X (2023) TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-\u03baB signaling pathway. Aging (Albany NY) 15:8013\u20138025. https:\/\/doi.org\/10.18632\/aging.204941","journal-title":"Aging (Albany NY)"},{"key":"4966_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/cmi.2015.103","volume":"14","author":"X Xu","year":"2017","unstructured":"Xu X, Meng Q, Erben U et al (2017) Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner. Cell Mol Immunol 14:597\u2013606. https:\/\/doi.org\/10.1038\/cmi.2015.103","journal-title":"Cell Mol Immunol"},{"key":"4966_CR35","first-page":"277","volume":"4","author":"Z Ye","year":"2007","unstructured":"Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J (2007) Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell Mol Immunol 4:277\u2013285","journal-title":"Cell Mol Immunol"},{"key":"4966_CR36","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509\u20138521. https:\/\/doi.org\/10.1002\/jcp.27782","journal-title":"J Cell Physiol"},{"key":"4966_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS (2020) The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol 30:695\u2013704. https:\/\/doi.org\/10.1016\/j.tcb.2020.06.003","journal-title":"Trends Cell Biol"},{"key":"4966_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C (2023) CD4(+) T cells in cancer. Nat Cancer 4:317\u2013329. https:\/\/doi.org\/10.1038\/s43018-023-00521-2","journal-title":"Nat Cancer"},{"key":"4966_CR39","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1002\/mco2.390","volume":"4","author":"L Xie","year":"2023","unstructured":"Xie L, Fang J, Yu J, Zhang W, He Z, Ye L, Wang H (2023) The role of CD4(+) T cells in tumor and chronic viral immune responses. MedComm (2020) 4:e390. https:\/\/doi.org\/10.1002\/mco2.390","journal-title":"MedComm (2020)"},{"key":"4966_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D (2024) Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-024-00859-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4966_CR41","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41467-020-15569-2","volume":"11","author":"B Zuo","year":"2020","unstructured":"Zuo B, Qi H, Lu Z et al (2020) Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice. Nat Commun 11:1790. https:\/\/doi.org\/10.1038\/s41467-020-15569-2","journal-title":"Nat Commun"},{"key":"4966_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005241","author":"M Jiang","year":"2022","unstructured":"Jiang M, Yang Y, Niu L et al (2022) MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005241","journal-title":"J Immunother Cancer"},{"key":"4966_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003508","author":"A Moatti","year":"2022","unstructured":"Moatti A, Debesset A, Pilon C et al (2022) TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003508","journal-title":"J Immunother Cancer"},{"key":"4966_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1","journal-title":"J Hematol Oncol"},{"key":"4966_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1177","volume":"9","author":"DJ Zanker","year":"2020","unstructured":"Zanker DJ, Spurling AJ, Brockwell NK et al (2020) Intratumoral administration of the Toll-like receptor 7\/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin Transl Immunol 9:e1177. https:\/\/doi.org\/10.1002\/cti2.1177","journal-title":"Clin Transl Immunol"},{"key":"4966_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX (2021) Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 14:156. https:\/\/doi.org\/10.1186\/s13045-021-01164-5","journal-title":"J Hematol Oncol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-04966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-04966-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-04966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T08:26:04Z","timestamp":1735806364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-04966-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4966"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-04966-6","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"24 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflict of interest was reported by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments have been approved by the Animal Protection and Use Committee of Guizhou Provincial People's Hospital (AIIimaD2020-005).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}